AnaptysBio, Inc. (ANAB)
| Previous Close | 18.87 |
| Open | 18.92 |
| Bid | 20.17 x 200 |
| Ask | 20.46 x 100 |
| Day's Range | 18.72 - 20.33 |
| 52 Week Range | 13.36 - 27.50 |
| Volume | |
| Avg. Volume | 327,327 |
| Market Cap | 554.158M |
| Beta (5Y Monthly) | -0.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.08 |
| Earnings Date | May 09, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 45.22 |
PR NewswireActym Therapeutics Appoints Thomas Smart as CEO
Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical eval
ZacksWhy You Shouldn't Bet Against AnaptysBio (ANAB) Stock.
AnaptysBio (ANAB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Simply Wall St.Industry Analysts Just Made A Stunning Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts
AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders will have a reason to smile today, with the analysts making substantial...
